Created On: 2020-07-15
Record Count: 6
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 256265
– regarding patents:
– – an exclusive License for the Territory to perform research, to make, have made, develop, sell, have sold and use the Compound in the Field.
– – an exclusive License for the Territory, to develop, to register, to make, have made, use, import, sell and have sold Products in the Field.
– regarding Know-How:
– – an exclusive License for the Territory to make, have made, develop, sell, have sold and use the Compound and Product in the Field.
IPSCIO Record ID: 245716
Licensee desires to obtain an exclusive license to patents owned or controlled by Licensor, a sublicense to certain patents licensed from Bristol-Myers Squibb Company (â€œBMSâ€), along with any associated know-how, biologic materials, clinical data or other technology relating to IL-6 receptor monoclonal antibodies (identified as NI-1201), and their use in order to research, develop and commercialize products and services.
IPSCIO Record ID: 26633
IPSCIO Record ID: 227285
IPSCIO Record ID: 283821
For the Option Right of the Licensee to the Optional Territory Licensor grants a non-exclusive option right to obtain an exclusive license, with the right to grant sublicenses to Sublicensees, under Licensor Intellectual Property and Know-How; and a non-exclusive option right to obtain an exclusive sublicense, with the right to grant sub-sublicenses to Sub-sublicensees, under Sublicensed Intellectual Property, to research, develop, make, have made, import, use, sell and offer to sell the Licensed Product in the Field in the mutually agreed upon countries in the Optional Territory,
Licensed Compound means FE301, i.e., SGP130Fc fusion protein, an interleukin-6 inhibitor.
The patents are for FE301 composition; FE301 dosing; Fusion proteins comprising two soluble gp130 molecules; Optimized nucleotide sequences encoding sgp130; and Improved sgp130Fc dimers.
Optimized nucleotide sequences encoding sgp130: Patent No. 8,206,948
Olamkicept is a new recombinant protein inhibitor of the interleukin-6 pathway. Interleukin-6 is associated with numerous inflammatory conditions such as inflammatory bowel diseases (IBD) and rheumatoid arthritis.
IPSCIO Record ID: 76567